{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:02:30Z","timestamp":1783573350275,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ijcard.2014.10.150","type":"journal-article","created":{"date-parts":[[2014,10,25]],"date-time":"2014-10-25T01:30:06Z","timestamp":1414200606000},"page":"8-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension"],"prefix":"10.1016","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1260-1308","authenticated-orcid":false,"given":"Francesco","family":"Pelliccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rosano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Volterrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Gaudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2014.10.150_bb0005","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1056\/NEJMoa003417","article-title":"Impact of high-normal blood pressure on the risk of cardiovascular disease","volume":"245","author":"Vasan","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0010","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMcp010357","article-title":"Initial treatment of hypertension","volume":"348","author":"August","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.18553\/jmcp.2007.13.s8-b.9","article-title":"The renin\u2013angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition","volume":"13","author":"Atlas","year":"2007","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrendo.2009.263","article-title":"Aldosterone and arterial hypertension","volume":"6","author":"Tomaschitz","year":"2010","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0025","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/HYPERTENSIONAHA.108.111211","article-title":"Aldosterone, hypertension, and cardiovascular disease: an endless story","volume":"52","author":"Ruilope","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2014.10.150_bb0030","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/HYPERTENSIONAHA.108.119966","article-title":"Reconsidering the roles of the mineralocorticoid receptor","volume":"53","author":"Funder","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2014.10.150_bb0035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/CIRCULATIONAHA.108.816108","article-title":"Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart Study","volume":"119","author":"Lieb","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.10.150_bb0040","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00424-008-0616-0","article-title":"Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?","volume":"458","author":"Gekle","year":"2009","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0045","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.amjhyper.2004.08.026","article-title":"Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension","volume":"18","author":"Mahmud","year":"2005","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0050","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.amjmed.2006.03.038","article-title":"Aldosterone blockade: an emerging strategy for abrogating progressive renal disease","volume":"119","author":"Epstein","year":"2006","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0055","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0060","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy. The 4E-left ventricular hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.10.150_bb0065","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7326\/0003-4819-150-11-200906020-00005","article-title":"Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension","volume":"150","author":"Sowers","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0070","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jash.2008.05.005","article-title":"Effectiveness of the selective aldosterone antagonist eplerenone in treating resistant hypertension","volume":"2","author":"Calhoun","year":"2008","journal-title":"J. Am. Soc. Hypertens."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0075","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0140-6736(62)92199-2","article-title":"The effects of spironolactone and chlorthalidone on arterial pressure","volume":"1","author":"Cranston","year":"1962","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2014.10.150_bb0080","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/HJH.0b013e32832810ed","article-title":"Aldosterone-receptor antagonism in hypertension","volume":"27","author":"Jansen","year":"2009","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0085","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1751-7176.2011.00511.x","article-title":"Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics","volume":"13","author":"Epstein","year":"2011","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0090","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1291\/hypres.25.837","article-title":"Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension","volume":"25","author":"Sato","year":"2002","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0095","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1253\/circj.70.995","article-title":"Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy","volume":"70","author":"Taniguchi","year":"2006","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0100","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1074248413497257","article-title":"Diuretics: a review and update.","volume":"19","author":"Roush","year":"2014","journal-title":". J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ijcard.2014.10.150_bb0105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1524-6175.2004.03146.x","article-title":"Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double blind, placebo-controlled, dose-ranging study","volume":"6","author":"Saruta","year":"2004","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin\u2013angiotensin blockade in hypertensive patients","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2014.10.150_bb0115","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","article-title":"Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension","volume":"41","author":"White","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2014.10.150_bb0120","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.amjcard.2004.01.007","article-title":"Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension","volume":"93","author":"Williams","year":"2004","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0125","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","article-title":"Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients","volume":"41","author":"Flack","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0130","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/S0149-2918(03)80282-5","article-title":"Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension","volume":"25","author":"Burgess","year":"2003","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0135","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"5","author":"Weinberger","year":"2002","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0140","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0002-9149(03)00461-2","article-title":"Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension","volume":"92","author":"White","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0145","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ahj.2004.12.005","article-title":"Effects of eplerenone versus losartan in patients with low-renin hypertension","volume":"150","author":"Weinberger","year":"2005","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0150","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.10.150_bb0155","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/clpt.2011.227","article-title":"Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension","volume":"91","author":"Fujimura","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0160","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/jhh.2009.81","article-title":"Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension","volume":"24","author":"Sato","year":"2010","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0165","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/archinte.163.13.1543","article-title":"Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension","volume":"163","author":"Hollenberg","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0170","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2014.10.150_bb0175","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527314020877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527314020877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T16:55:10Z","timestamp":1650473710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527314020877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":35,"alternative-id":["S0167527314020877"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2014.10.150","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2014.10.150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}